Circulating micrornas in hepatocellular carcinoma: Potential diagnostic and prognostic biomarkers

Current Pharmaceutical Design

Volumn 22, Issue 34, 2016, Pages 5257-5269

  Mirzaei, Hamid Reza ^a   Sahebkar, Amirhossein ^b   Mohammadi, Mohsen ^c   Yari, Reza ^d   Salehi, Hossein ^e   Jafari, Mohammad Hasan ^b   Namdar, Afshin ^e   Khabazian, Ehsan ^f   Jaafari, Mahmoud Reza ^g   Mirzaei, Hamed ^b  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c LORESTAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d ISLAMIC AZAD UNIVERSITY   (Iran)

^e ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^f TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^g MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Cancer; Diagnosis; Hepatocellular carcinoma; MicroRNA; Prognosis

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; DOXORUBICIN; FLUOROURACIL; MICRORNA; MICRORNA 100; MICRORNA 101; MICRORNA 122; MICRORNA 125B; MICRORNA 141; MICRORNA 146A; MICRORNA 155; MICRORNA 16; MICRORNA 192; MICRORNA 20A; MICRORNA 20B; MICRORNA 21; MICRORNA 210; MICRORNA 214; MICRORNA 222; MICRORNA 223; MICRORNA 375; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN P21; PROTEIN P53; STAT3 PROTEIN; TUMOR MARKER; VINCRISTINE; CIRCULATING MICRORNA;

ANTINEOPLASTIC ACTIVITY; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER SURVIVAL; CELL CYCLE ARREST; DIAGNOSTIC VALUE; DOWN REGULATION; DRUG SENSITIVITY; GENE EXPRESSION REGULATION; HUMAN; LIVER CELL CARCINOMA; NONHUMAN; ONCOGENE C MYC; PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE; UPREGULATION; ANIMAL; BLOOD; LIVER TUMOR;

ANIMALS; BIOMARKERS, TUMOR; CARCINOMA, HEPATOCELLULAR; CIRCULATING MICRORNA; HUMANS; LIVER NEOPLASMS;

EID: 84995920428     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612822666160303110838     Document Type: Review

References (178)

1. Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA: a cancer journal for clinicians. CA Cancer J Clin 2015; 65 (2): 87-108.
2. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012; 142 (6): 1264-73e1.
3. Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 2008; 48 (2): 335-52.
4. Benson 3rd A, Abrams TA, Ben-Josef E, et al. NCCN clinical practice guidelines in oncology: hepatobiliary cancers. J Natl Comprehens Cancer Netw 2009; 7 (4): 350.
5. Zinkin NT, Grall F, Bhaskar K, et al. Serum proteomics and biomarkers in hepatocellular carcinoma and chronic liver disease. Clin Cancer Res 2008; 14 (2): 470-7.
6. Sherman M. Screening for hepatocellular carcinoma. Hepatol Res 2007; 37 (s2): S152-65.
7. Oka H, Tamori A, Kuroki T, Kobayashi K, Yamamoto S. Prospective study of alpha-fetoprotein in cirrhotic patients monitored for development of hepatocellular carcinoma. Hepatology (Baltimore, Md) 1994; 19 (1): 61-6.
8. Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 2008; 105 (30): 10513-8.
9. Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet 2009; 10 (10): 704-14.
10. Gramantieri L, Fornari F, Callegari E, et al. MicroRNA involvement in hepatocellular carcinoma. J Cell Mol Med 2008; 12 (6a): 2189-204.
11. Mott JL. MicroRNAs involved in tumor suppressor and oncogene pathways: implications for hepatobiliary neoplasia. Hepatology (Baltimore, Md) 2009; 50 (2): 630-7.
12. Di Leva G, Croce CM. miRNA profiling of cancer. Curr Opin Gen Develop 2013; 23 (1): 3-11.
13. Liu AM, Yao TJ, Wang W, et al. Circulating miR-15b and miR-130b in serum as potential markers for detecting hepatocellular carcinoma: a retrospective cohort study. BMJ Open 2012; 2 (2): e000825.
14. Arroyo JD, Chevillet JR, Kroh EM, et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci USA 2011; 108 (12): 5003-8.
15. Nilsson RJA, Balaj L, Hulleman E, van Rijn S, Pegtel DM, Walraven M, et al. Blood platelets contain tumor-derived RNA biomarkers. Blood 2011; 118 (13): 3680-3.
16. Chen X, Ba Y, Ma L, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008; 18 (10): 997-1006.
17. Cortez MA, Bueso-Ramos C, Ferdin J, et al. MicroRNAs in body fluids—the mix of hormones and biomarkers. Nat Rev Clin Oncol 2011; 8 (8): 467-77.
18. Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers. Nature 2005; 435 (7043): 834-8.
19. Tan Y, Ge G, Pan T, et al. A Serum MicroRNA Panel as Potential Biomarkers for Hepatocellular Carcinoma Related with Hepatitis B Virus. PloS One 2014; 9 (9): e107986.
20. Murakami Y, Yasuda T, Saigo K, et al. Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene 2006; 25 (17): 2537-45.
21. Connolly E, Melegari M, Landgraf P, et al. Elevated expression of the miR-17–92 polycistron and miR-21 in hepadnavirus-associated hepatocellular carcinoma contributes to the malignant phenotype. Am J Pathol 2008; 173 (3): 856-64.
22. Liu Y, Zhang Y, Wen J, et al. A genetic variant in the promoter region of miR-106b-25 cluster and risk of HBV infection and hepatocellular carcinoma. PLoS One 2012; 7 (2): e32230.
23. Jiang J, Gusev Y, Aderca I, et al. Association of MicroRNA expression in hepatocellular carcinomas with hepatitis infection, cirrhosis, and patient survival. Clin Cancer Res 2008; 14 (2): 419-27.
24. Landgraf P, Rusu M, Sheridan R, et al. A mammalian microRNA expression atlas based on small RNA library sequencing. Cell 2007; 129 (7): 1401-14.
25. Wang B, Majumder S, Nuovo G, et al. Role of microRNA-155 at early stages of hepatocarcinogenesis induced by choline-deficient and amino acid-defined diet in C57BL/6 mice. Hepatology (Baltimore, Md) 2009; 50 (4): 1152-61.
26. Meng F, Henson R, Wehbe-Janek H, et al. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 2007; 133 (2): 647-58.
27. Meng F, Henson R, Lang M, et al. Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. Gastroenterology 2006; 130 (7): 2113-29.
28. Yamamoto Y, Kosaka N, Tanaka M, et al. MicroRNA-500 as a potential diagnostic marker for hepatocellular carcinoma. Biomarkers: biochemical indicators of exposure, response, and susceptibility to chemicals. Biomolecules 2009; 14 (7): 529-38.
29. Shigoka M, Tsuchida A, Matsudo T, et al. Deregulation of miR-92a expression is implicated in hepatocellular carcinoma development. Pathol Int 2010; 60 (5): 351-7.
30. Gramantieri L, Ferracin M, Fornari F, et al. Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. Cancer Res 2007; 67 (13): 6092-9.
31. Targeting A. miRNA-302b suppresses human hepatocellular carcinoma by. Mol Cancer Res 2014; 12 (2): 190.
32. Wong QW, Ching AK, Chan AW, et al. MiR-222 overexpression confers cell migratory advantages in hepatocellular carcinoma through enhancing AKT signaling. Clin Cancer Res 2010; 16 (3): 867-75.
33. Fornari F, Gramantieri L, Ferracin M, et al. MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma. Oncogene 2008; 27 (43): 5651-61.
34. Lee Y, Jeon K, Lee JT, Kim S, Kim VN. MicroRNA maturation: stepwise processing and subcellular localization. EMBO J 2002; 21 (17): 4663-70.
35. Lee Y, Ahn C, Han J, et al. The nuclear RNase III Drosha initiates microRNA processing. Nature 2003; 425 (6956): 415-9.
36. Zeng Y, Cullen BR. Structural requirements for pre-microRNA binding and nuclear export by Exportin 5. Nucleic Acids Res 2004; 32 (16): 4776-85.
37. Kim VN. MicroRNA precursors in motion: exportin-5 mediates their nuclear export. Trends Cell Biol 2004; 14 (4): 156-9.
38. Berezikov E, Guryev V, van de Belt J, et al. Phylogenetic shadowing and computational identification of human microRNA genes. Cell 2005; 120 (1): 21-4.
39. Valadi H, Ekstrom K, Bossios A, et al. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 2007; 9 (6): 654-9.
40. Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 2008; 105 (30): 10513-8.
41. Hanke M, Hoefig K, Merz H, et al. A robust methodology to study urine microRNA as tumor marker: microRNA-126 and microRNA-182 are related to urinary bladder cancer. Urol Oncol 2010; 28 (6): 655-61.
42. Park NJ, Zhou H, Elashoff D, Henson BS, et al. Salivary microRNA: discovery, characterization, and clinical utility for oral cancer detection. Clin Cancer Res 2009; 15 (17): 5473-7.
43. Morkin E. Control of cardiac myosin heavy chain gene expression. Microsc Res Tech 2000; 50 (6): 522-31.
44. Hunter MP, Ismail N, Zhang X, et al. Detection of microRNA expression in human peripheral blood microvesicles. PloS One 2008; 3 (11): e3694.
45. Valadi H, Ekström K, Bossios A, et al. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 2007; 9 (6): 654-9.
46. Giordano S, Columbano A. MicroRNAs: new tools for diagnosis, prognosis, and therapy in hepatocellular carcinoma? Hepatology 2013; 57 (2): 840-7.
47. Bala S, Petrasek J, Mundkur S, et al. Circulating microRNAs in exosomes indicate hepatocyte injury and inflammation in alcoholic, drug-induced, and inflammatory liver diseases. Hepatology 2012; 56 (5): 1946-57.
48. Blanco-Calvo M, Calvo L, Figueroa A, et al. Circulating microRNAs: molecular microsensors in gastrointestinal cancer. Sensors 2012; 12 (7): 9349-62.
49. Ge Y, Chen G, Sun L, Liu F. [MicroRNA-29 and fibrosis diseases]. Zhong Nan da xue xue bao Yi xue ban= 2011; 36 (9): 908-12.
50. He Y, Huang C, Zhang S-p, Sun X, Long X-r, Li J. The potential of microRNAs in liver fibrosis. Cell Signal 2012; 24 (12): 2268-72.
51. Cermelli S, Ruggieri A, Marrero JA, Ioannou GN, Beretta L. Circulating microRNAs in patients with chronic hepatitis C and non-alcoholic fatty liver disease. PloS One 2011; 6 (8): e23937.
52. Chen Yp, Jin X, Xiang Z, Chen Sh, Li Ym. Circulating MicroRNAs as potential biomarkers for alcoholic steatohepatitis. Liver Int 2013; 33 (8): 1257-65.
53. Chen Y-J, Zhu J-M, Wu H, et al. Circulating microRNAs as a fingerprint for liver cirrhosis. PloS One 2013; 8 (6): e66577.
54. Chen X, Ba Y, Ma L, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008; 18 (10): 997-1006.
55. Kutay H, Bai S, Datta J, et al. Downregulation of miR-122 in the rodent and human hepatocellular carcinomas. J Cell Biochem 2006; 99 (3): 671-8.
56. Ladeiro Y, Couchy G, Balabaud C, et al. MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations. Hepatology 2008; 47 (6): 1955-63.
57. Li L-M, Hu Z-B, Zhou Z-X, et al. Serum microRNA profiles serve as novel biomarkers for HBV infection and diagnosis of HBVpositive hepatocarcinoma. Cancer Res 2010; 70 (23): 9798-807.
58. Meng F, Henson R, Wehbe-Janek H, et al. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 2007; 133 (2): 647-58.
59. Pineau P, Volinia S, McJunkin K, et al. MiR-221 overexpression contributes to liver tumorigenesis. Proc Natl Acad Sci USA 2010; 107 (1): 264-9.
60. Xu J, Wu C, Che X, et al. Circulating MicroRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis. Mol Carcinog 2011; 50 (2): 136-42.
61. Xu J, Wu C, Che X, et al. Circulating MicroRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis. Mol Carcinog 2011; 50 (2): 136-42.
62. Qu KZ, Zhang K, Li H, et al. Circulating microRNAs as biomarkers for hepatocellular carcinoma. J Clin Gastroenterol 2011; 45 (4): 355-60.
63. Tomimaru Y, Eguchi H, Nagano H, et al. Circulating microRNA-21 as a novel biomarker for hepatocellular carcinoma. J Hepatol 2012; 56 (1): 167-75.
64. Qi P, Cheng S., Wang H, et al. Serum microRNAs as biomarkers for hepatocellular carcinoma in Chinese patients with chronic hepatitis B virus infection. PloS One 2011; 6 (12): e28486.
65. Li J, Wang Y, Yu W, Chen J, Luo J. Expression of serum miR-221 in human hepatocellular carcinoma and its prognostic significance. Biochem Biophys Res Commun 2011; 406 (1): 70-3.
66. Li LM, Hu ZB, Zhou ZX, et al. Serum microRNA profiles serve as novel biomarkers for HBV infection and diagnosis of HBV-positive hepatocarcinoma. Cancer Res 2010; 70 (23): 9798-807.
67. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006; 6 (11): 857-66.
68. Calin GA, Ferracin M, Cimmino A, et al. A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 2005; 353 (17): 1793-801.
69. Schetter AJ, Leung SY, Sohn JJ, et al. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA 2008; 299 (4): 425-36.
70. Zheng J, Dong P, Gao S, Wang N, Yu F. High expression of serum miR-17-5p associated with poor prognosis in patients with hepatocellular carcinoma. Hepatogastroenterology 2013; 60 (123): 549-52.
71. Wei X, Tan C, Tang C, et al. Epigenetic repression of miR-132 expression by the hepatitis B virus x protein in hepatitis B virusrelated hepatocellular carcinoma. Cell Signal 2013; 25 (5): 1037-43.
72. Li L, Guo Z, Wang J, Mao Y, Gao Q. Serum miR-18a: a potential marker for hepatitis B virus-related hepatocellular carcinoma screening. Digest Dis Sci 2012; 57 (11): 2910-6.
73. Li L, Guo Z, Wang J, Mao Y, Gao Q. Serum miR-18a: a potential marker for hepatitis B virus-related hepatocellular carcinoma screening. Digest Dis Sci 2012; 57 (11): 2910-6.
74. Fu Y, Wei X, Tang C, et al. Circulating microRNA-101 as a potential biomarker for hepatitis B virus-related hepatocellular carcinoma. Oncol Lett 2013; 6 (6): 1811-5.
75. Zhan M, Li Y, Hu B, et al. [Expression of serum microRNAs (miR-222, miR-181, miR-216) in human hepatocellular carcinoma and its clinical significance]. Zhonghua yi xue za zhi 2013; 93 (23): 1830-2.
76. Zhou J, Yu L, Gao X, et al. Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma. J Clin Oncol 2011; 29 (36): 4781-8.
77. Wei R, Huang GL, Zhang MY, et al. Clinical significance and prognostic value of microRNA expression signatures in hepatocellular carcinoma. Clin Cancer Res 2013; 19 (17): 4780-91.
78. Wu N, Liu X, Xu X, et al. MicroRNA-373, a new regulator of protein phosphatase 6, functions as an oncogene in hepatocellular carcinoma. FEBS J 2011; 278 (12): 2044-54.
79. Murakami Y, Tamori A, Itami S, et al. The expression level of miR-18b in hepatocellular carcinoma is associated with the grade of malignancy and prognosis. BMC Cancer 2013; 13: 99.
80. Fan MQ, Huang CB, Gu Y, et al. Decrease expression of microRNA-20a promotes cancer cell proliferation and predicts poor survival of hepatocellular carcinoma. J Exp Clin Cancer Res 2013; 32 (1): 21.
81. Ura S, Honda M, Yamashita T, et al. Differential microRNA expression between hepatitis B and hepatitis C leading disease progression to hepatocellular carcinoma. Hepatology 2009; 49 (4): 1098-112.
82. Xu J, Wu C, Che X, et al. Circulating microRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis. Mol Carcinog 2011; 50 (2): 136-42.
83. Huang YH, Lin KH, Chen HC, et al. Identification of postoperative prognostic microRNA predictors in hepatocellular carcinoma. PLoS One 2012; 7 (5): e37188.
84. Shen J, Wang A, Wang Q, et al. Exploration of genome-wide circulating microRNA in hepatocellular carcinoma: MiR-483-5p as a potential biomarker. Cancer Epidemiology, Biomarkers Prevent 2013; 22 (12): 2364-73.
85. Gregory PA, Bert AG, Paterson EL, et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 2008; 10 (5): 593-601.
86. Yeh TS, Wang F, Chen TC, et al. Expression profile of microRNA-200 family in hepatocellular carcinoma with bile duct tumor thrombus. Ann Surg 2014; 259 (2): 346-54.
87. Yan Y, Luo YC, Wan HY, et al. MicroRNA-10a is involved in the metastatic process by regulating Eph tyrosine kinase receptor A4-mediated epithelial-mesenchymal transition and adhesion in hepatoma cells. Hepatology (Baltimore, Md) 2013; 57 (2): 667-77.
88. Qu KZ, Zhang K, Li H, Afdhal NH, Albitar M. Circulating microRNAs as biomarkers for hepatocellular carcinoma. J Clin Gastroenterol 2011; 45 (4): 355-60.
89. Yao J, Liang LH, Zhang Y, et al. GNAI1 suppresses tumor cell migration and invasion and is post-transcriptionally regulated by Mir-320a/c/d in hepatocellular carcinoma. Cancer Biol Med 2012; 9 (4): 234-41.
90. Gui J, Tian Y, Wen X, et al. Serum microRNA characterization identifies miR-885-5p as a potential marker for detecting liver pathologies. Clin Sci (London, England: 1979) 2011; 120 (5): 183-93.
91. Liu F, You X, Chi X, et al. Hepatitis B virus X protein mutant HBxDelta127 promotes proliferation of hepatoma cells through upregulating miR-215 targeting PTPRT. Biochem Biophys Res Commun 2014; 444 (2): 128-34.
92. Zhang Z, Yin J, Lv D, et al. MiR-885-5p, a p53-activated microRNA, inhibits the Wnt/{beta}-catenin signaling pathway and hepatocellular carcinoma metastasis. Cancer Res 2013; 73: 3081.
93. Roderburg C, Mollnow T, Bongaerts B, et al. Micro-RNA profiling in human serum reveals compartment-specific roles of miR-571 and miR-652 in liver cirrhosis. PLoS One 2012; 7 (3): e32999.
94. Yu F, Shen XY, Fan L, Yu ZC. Genome-wide analysis of genetic variations assisted by Ingenuity Pathway Analysis to comprehensively investigate potential genetic targets associated with the progression of hepatocellular carcinoma. Eur Rev Med Pharmacol Sci 2014; 18 (15): 2102-8.
95. Roderburg C, Mollnow T, Bongaerts B, et al. Micro-RNA profiling in human serum reveals compartment-specific roles of miR-571 and miR-652 in liver cirrhosis. PLoS One 2012; 7 (3): e32999.
96. Zhuang LP, Meng ZQ. Serum miR-224 reflects stage of hepatocellular carcinoma and predicts survival. BioMed Res Int 2015; 2015: 731-81.
97. Zhou P, Jiang W, Wu L, et al. MiR-301a is a candidate oncogene that targets the homeobox gene Gax in human hepatocellular carcinoma. Digest Dis Sci 2012; 57 (5): 1171-80.
98. Liu S, Guo W, Shi J, et al. MicroRNA-135a contributes to the development of portal vein tumor thrombus by promoting metastasis in hepatocellular carcinoma. J Hepatol 2012; 56 (2): 389-96.
99. Ko KS, Peng H, Tang H, et al. Recent advances of miRNA involvement in hepatocellular carcinoma and cholangiocarcinoma. Open J Internal Med 2012; 2: 135-62.
100. Tian Q, Liang L, Ding J, et al. MicroRNA-550a acts as a prometastatic gene and directly targets cytoplasmic polyadenylation element-binding protein 4 in hepatocellular carcinoma. PLoS One 2012; 7 (11): e48958.
101. El Tayebi HM, Hosny KA, Esmat G, Breuhahn K, Abdelaziz AI. miR-615-5p is restrictedly expressed in cirrhotic and cancerous liver tissues and its overexpression alleviates the tumorigenic effects in hepatocellular carcinoma. FEBS Lett 2012; 586 (19): 3309-16.
102. Zhang L, Yang L, Liu X, et al. MicroRNA-657 promotes tumorigenesis in hepatocellular carcinoma by targeting transducinlike enhancer protein 1 through nuclear factor kappa B pathways. Hepatology (Baltimore, Md) 2013; 57 (5): 1919-30.
103. Fornari F, Milazzo M, Chieco P, et al. In hepatocellular carcinoma miR-519d is up-regulated by p53 and DNA hypomethylation and targets CDKN1A/p21, PTEN, AKT3 and TIMP2. J Pathol 2012; 227 (3): 275-85.
104. Wang W, Zhao LJ, Tan Y-X, Ren H, Qi Z-T. Identification of deregulated miRNAs and their targets in hepatitis B virusassociated hepatocellular carcinoma. World J Gastroenterol 2012; 18 (38): 5442.
105. Yang H, Zheng W, Zhao W, Guan C, An J. [Roles of miR-590-5p and miR-590-3p in the development of hepatocellular carcinoma]. Nan fang yi ke da xue xue bao 2013; 33 (6): 804-11
106. Huang S, He R, Rong M, Dang Y, Chen G. Synergistic effect of MiR-146a mimic and cetuximab on hepatocellular carcinoma cells. BioMed Res Int 2014; 2014: 384121.
107. Sun G, Shi L, Yan S, et al. MiR-15b targets cyclin D1 to regulate proliferation and apoptosis in glioma cells. BioMed Res Int 2014; 2014: 687826.
108. Zhang W, Kong G, Zhang J, et al. MicroRNA-520b inhibits growth of hepatoma cells by targeting MEKK2 and cyclin D1. PLoS One 2012; 7 (2): e31450.
109. Lin J, Huang S, Wu S, et al. MicroRNA-423 promotes cell growth and regulates G (1) /S transition by targeting p21Cip1/Waf1 in hepatocellular carcinoma. Carcinogenesis 2011; 32 (11): 1641-7.
110. Law PT, Qin H, Ching AK, et al. Deep sequencing of small RNA transcriptome reveals novel non-coding RNAs in hepatocellular carcinoma. J Hepatol 2013; 58 (6): 1165-73.
111. Lim L, Balakrishnan A, Huskey N, et al. MicroRNA-494 within an oncogenic microRNA megacluster regulates G1/S transition in liver tumorigenesis through suppression of mutated in colorectal cancer. Hepatology (Baltimore, Md) 2014; 59 (1): 202-15.
112. Yao YL, Wu XY, Wu JH, et al. Effects of microRNA-106 on proliferation of gastric cancer cell through regulating p21 and E2F5. Asian Pacific J Cancer Prevent 2013; 14 (5): 2839-43.
113. Li Y, Tan W, Neo TW, et al. Role of the miR-106b-25 microRNA cluster in hepatocellular carcinoma. Cancer Sci 2009; 100 (7): 1234-42.
114. El-Garem H, Ammer A, Shehab H, et al. Circulating microRNA, miR-122 and miR-221 signature in Egyptian patients with chronic hepatitis C related hepatocellular carcinoma. World J Hepatol 2014; 6 (11): 818-24.
115. Liu YM, Xia Y, Dai W, et al. Cholesterol-conjugated let-7a mimics: antitumor efficacy on hepatocellular carcinoma in vitro and in a preclinical orthotopic xenograft model of systemic therapy. BMC Cancer 2014; 14: 889.
116. Abdalla MA, Haj-Ahmad Y. Promising candidate urinary microrna biomarkers for the early detection of hepatocellular carcinoma among high-risk hepatitis C virus egyptian patients. J Cancer 2012; 3: 19-31.
117. Li HP, Zeng XC, Zhang B, et al. miR-451 inhibits cell proliferation in human hepatocellular carcinoma through direct suppression of IKK-beta. Carcinogenesis 2013; 34 (11): 2443-51.
118. Katayama Y, Maeda M, Miyaguchi K, et al. Identification of pathogenesis-related microRNAs in hepatocellular carcinoma by expression profiling. Oncol Lett 2012; 4 (4): 817-23.
119. Zheng Y, Yin L, Chen H, et al. miR-376a suppresses proliferation and induces apoptosis in hepatocellular carcinoma. FEBS Lett 2012; 586 (16): 2396-403.
120. Zheng Y, Chen H, Yin M, et al. MiR-376a and histone deacetylation 9 form a regulatory circuitry in hepatocellular carcinoma. Cell Physiol Biochem 2015; 35 (2): 729-39.
121. Furuta M, Kozaki KI, Tanaka S, et al. miR-124 and miR-203 are epigenetically silenced tumor-suppressive microRNAs in hepatocellular carcinoma. Carcinogenesis 2010; 31 (5): 766-76.
122. Murakami Y, Yasuda T, Saigo K, et al. Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene 2006; 25 (17): 2537-45.
123. Huang N, Lin J, Ruan J, et al. MiR-219-5p inhibits hepatocellular carcinoma cell proliferation by targeting glypican-3. FEBS Lett 2012; 586 (6): 884-91.
124. Feng J, Wang J, Chen M, et al. MiR-200a suppresses cell growth and migration by targeting MACC1 and predicts prognosis in hepatocellular carcinoma. Oncol Rep 2015; 33 (2): 713-20.
125. Hung CS, Liu HH, Liu JJ, et al. MicroRNA-200a and-200b mediated hepatocellular carcinoma cell migration through the epithelial to mesenchymal transition markers. Ann Surg Oncol 2013; 20: S360-8.
126. Wong CC, Wong CM, Tung EK, et al. The microRNA miR-139 suppresses metastasis and progression of hepatocellular carcinoma by down-regulating Rho-kinase 2. Gastroenterology 2011; 140 (1): 322-31.
127. Fang Y, Xue JL, Shen Q, Chen J, Tian L. MicroRNA-7 inhibits tumor growth and metastasis by targeting the phosphoinositide 3-kinase/Akt pathway in hepatocellular carcinoma. Hepatology (Baltimore, Md) 2012; 55 (6): 1852-62.
128. Su H, Yang JR, Xu T, et al. MicroRNA-101, down-regulated in hepatocellular carcinoma, promotes apoptosis and suppresses tumorigenicity. Cancer Res 2009; 69 (3): 1135-42.
129. Li D, Yang P, Li H, et al. MicroRNA-1 inhibits proliferation of hepatocarcinoma cells by targeting endothelin-1. Life Sci 2012; 91 (11-12): 440-7.
130. Datta J, Kutay H, Nasser MW, et al. Methylation mediated silencing of MicroRNA-1 gene and its role in hepatocellular carcinogenesis. Cancer Res 2008; 68 (13): 5049-58.
131. Zhou J, Lu S, Yang S, et al. MicroRNA-127 post-transcriptionally downregulates Sept7 and suppresses cell growth in hepatocellular carcinoma cells. Cell Physiol Biochem 2014; 33 (5): 1537-46.
132. Tryndyak VP, Ross SA, Beland FA, Pogribny IP. Down-regulation of the microRNAs miR-34a, miR-127, and miR-200b in rat liver during hepatocarcinogenesis induced by a methyl-deficient diet. Mol Carcinog 2009; 48 (6): 479-87.
133. Cao G, Dong W, Meng X, et al. MiR-511 inhibits growth and metastasis of human hepatocellular carcinoma cells by targeting PIK3R3. Tumour Biol 2015; 36 (6): 4453-9.
134. Yang Z, Tsuchiya H, Zhang Y, Hartnett ME, Wang L. MicroRNA-433 inhibits liver cancer cell migration by repressing the protein expression and function of cAMP response element-binding protein. J Biol Chem 2013; 288 (40): 28893-9.
135. Hou J, Lin L, Zhou W, et al. Identification of miRNomes in human liver and hepatocellular carcinoma reveals miR-199a/b-3p as therapeutic target for hepatocellular carcinoma. Cancer Cell 2011; 19 (2): 232-43.
136. Bi Q, Tang S, Xia L, et al. Ectopic expression of MiR-125a inhibits the proliferation and metastasis of hepatocellular carcinoma by targeting MMP11 and VEGF. PLoS One 2012; 7 (6): e40169.
137. Kim JK, Noh JH, Jung KH, et al. Sirtuin7 oncogenic potential in human hepatocellular carcinoma and its regulation by the tumor suppressors MiR-125a-5p and MiR-125b. Hepatology (Baltimore, Md) 2013; 57 (3): 1055-67.
138. Wang B, Hsu SH, Majumder S, et al. TGFbeta-mediated upregulation of hepatic miR-181b promotes hepatocarcinogenesis by targeting TIMP3. Oncogene 2010; 29 (12): 1787-97.
139. Zhang J, Yang Y, Yang T, et al. MicroRNA-22, downregulated in hepatocellular carcinoma and correlated with prognosis, suppresses cell proliferation and tumourigenicity. Br J Cancer 2010; 103 (8): 1215-20.
140. Gailhouste L, Gomez-Santos L, Hagiwara K, et al. MiR-148a plays a pivotal role in the liver by promoting the hepatospecific phenotype and suppressing the invasiveness of transformed cells. Hepatology (Baltimore, Md) 2013; 58 (3): 1153-65.
141. Pan L, Huang S, He R, et al. Decreased expression and clinical significance of miR-148a in hepatocellular carcinoma tissues. Eur J Med Res 2014; 19 (1): 68.
142. Yan H, Dong X, Zhong X, et al. Inhibitions of epithelial to mesenchymal transition and cancer stem cells-like properties are involved in miR-148a-mediated anti-metastasis of hepatocellular carcinoma. Mol Carcinog 2014; 53 (12): 960-9.
143. Giordano S, Columbano A. MicroRNAs: new tools for diagnosis, prognosis, and therapy in hepatocellular carcinoma? Hepatology (Baltimore, Md) 2013; 57 (2): 840-7.
144. Kota J, Chivukula RR, O’Donnell KA, et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 2009; 137 (6): 1005-17.
145. Callegari E, Elamin BK, Giannone F, et al. Liver tumorigenicity promoted by microRNA-221 in a mouse transgenic model. Hepatology (Baltimore, Md) 2012; 56 (3): 1025-33.
146. Park JK, Kogure T, Nuovo GJ, et al. miR-221 silencing blocks hepatocellular carcinoma and promotes survival. Cancer Res 2011; 71 (24): 7608-16.
147. Hatziapostolou M, Polytarchou C, Aggelidou E, et al. An HNF4alpha-miRNA inflammatory feedback circuit regulates hepatocellular oncogenesis. Cell 2011; 147 (6): 1233-47.
148. Tao ZH, Wan JL, Zeng LY, et al. miR-612 suppresses the invasivemetastatic cascade in hepatocellular carcinoma. J Exp Med 2013; 210 (4): 789-803.
149. Zhang S, Shan C, Kong G, et al. MicroRNA-520e suppresses growth of hepatoma cells by targeting the NF-kappaB-inducing kinase (NIK). Oncogene 2012; 31 (31): 3607-20.
150. Zhang JG, Shi Y, Hong DF, Song M, Huang D, Wang CY, et al. MiR-148b suppresses cell proliferation and invasion in hepatocellular carcinoma by targeting WNT1/beta-catenin pathway. Scientific Rep 2015; 5: 8087.
151. Yang XW, Zhang LJ, Huang XH, et al. miR-145 suppresses cell invasion in hepatocellular carcinoma cells: miR-145 targets ADAM17. Hepatol Res 2014; 44 (5): 551-9.
152. Yang X, Zhang XF, Lu X, et al. MicroRNA-26a suppresses angiogenesis in human hepatocellular carcinoma by targeting hepatocyte growth factor-cMet pathway. Hepatology (Baltimore, Md) 2014; 59 (5): 1874-85.
153. Yunqiao L, Vanke H, Jun X, Tangmeng G. MicroRNA-206, downregulated in hepatocellular carcinoma, suppresses cell proliferation and promotes apoptosis. Hepatogastroenterology 2014; 61 (133): 1302-7.
154. Dang Y, Luo D, Rong M, Chen G. Underexpression of miR-34a in hepatocellular carcinoma and its contribution towards enhancement of proliferating inhibitory effects of agents targeting c-MET. PloS One 2013; 8 (4): e61054.
155. Salvi A, Sabelli C, Moncini S, et al. MicroRNA-23b mediates urokinase and c-met downmodulation and a decreased migration of human hepatocellular carcinoma cells. FEBS J 2009; 276 (11): 2966-82.
156. Hou W, Tian Q, Zheng J, Bonkovsky HL. MicroRNA-196 represses Bach1 protein and hepatitis C virus gene expression in human hepatoma cells expressing hepatitis C viral proteins. Hepatology (Baltimore, Md) 2010; 51 (5): 1494-504.
157. Mao K, Zhang J, He C, et al. Restoration of miR-193b sensitizes Hepatitis B virus-associated hepatocellular carcinoma to sorafenib. Cancer Lett 2014 1; 352 (2): 245-52.
158. Weng Z, Wang D, Zhao W, et al. microRNA-450a targets DNA methyltransferase 3a in hepatocellular carcinoma. Exp Ther Med 2011; 2 (5): 951-5.
159. Buurman R, Gurlevik E, Schaffer V, et al. Histone deacetylases activate hepatocyte growth factor signaling by repressing microRNA-449 in hepatocellular carcinoma cells. Gastroenterology 2012; 143 (3): 811-20 e1-15.
160. Dang YW, Zeng J, He RQ, et al. Effects of miR-152 on cell growth inhibition, motility suppression and apoptosis induction in hepatocellular carcinoma cells. Asian Pacific J Cancer Prevent 2014; 15 (12): 4969-76.
161. Zhu XC, Dong QZ, Zhang XF, et al. microRNA-29a suppresses cell proliferation by targeting SPARC in hepatocellular carcinoma. Int J Mol Med 2012; 30 (6): 1321-6.
162. Yang H, Fang F, Chang R, Yang L. MicroRNA-140-5p suppresses tumor growth and metastasis by targeting transforming growth factor beta receptor 1 and fibroblast growth factor 9 in hepatocellular carcinoma. Hepatology (Baltimore, Md) 2013; 58 (1): 205-17.
163. Ma Y, She XG, Ming YZ, Wan QQ. MiR-24 promotes the proliferation and invasion of HCC cells by targeting SOX7. Tumour Biol 2014; 35 (11): 10731-6.
164. Liao CG, Kong LM, Zhou P, et al. MiR-10b is overexpressed in hepatocellular carcinoma and promotes cell proliferation, migration and invasion through RhoC, uPAR and MMPs. J Trans Med 2014; 12 (1): 234.
165. Zhang LY, Liu M, Li X, Tang H. MiR-490-3p modulates cell growth and epithelial to mesenchymal transition of hepatocellular carcinoma cells by targeting endoplasmic reticulum-Golgi intermediate compartment protein 3 (ERGIC3). J Biol Chem 2013; 288 (6): 4035-47.
166. Wu XJ, Li Y, Liu D, et al. miR-27a as an oncogenic microRNA of hepatitis B virus-related hepatocellular carcinoma. Asian Pacific J Cancer Prevent 2013; 14 (2): 885-9.
167. Yang YF, Wang F, Xiao JJ, et al. MiR-222 overexpression promotes proliferation of human hepatocellular carcinoma HepG2 cells by downregulating p27. Int J Clin Exp Med 2014; 7 (4): 893-902.
168. Elyakim E, Sitbon E, Faerman A, et al. hsa-miR-191 is a candidate oncogene target for hepatocellular carcinoma therapy. Cancer Res 2010; 70 (20): 8077-87.
169. Wu K, Ding J, Chen C, et al. Hepatic transforming growth factor beta gives rise to tumor-initiating cells and promotes liver cancer development. Hepatology (Baltimore, Md) 2012; 56 (6): 2255-67.
170. Zhang X, Liu S, Hu T, et al. Up-regulated microRNA-143 transcribed by nuclear factor kappa B enhances hepatocarcinoma metastasis by repressing fibronectin expression. Hepatology (Baltimore, Md) 2009; 50 (2): 490-9.
171. Wang Y, Lu Z, Li Y, et al. [miR-143 inhibits proliferation and invasion of hepatocellular carcinoma cells via down-regulation of TLR2 expression]. Xi bao yu fen zi mian yi xue za zhi 2014; 30 (10): 1076-9.
172. Yang H, Cho ME, Li TW, et al. MicroRNAs regulate methionine adenosyltransferase 1A expression in hepatocellular carcinoma. J Clin Invest 2013; 123 (1): 285-98.
173. Xu Y, Xia F, Ma L, et al. MicroRNA-122 sensitizes HCC cancer cells to adriamycin and vincristine through modulating expression of MDR and inducing cell cycle arrest. Cancer Lett 2011; 310 (2): 160-9.
174. Fornari F, Gramantieri L, Giovannini C, et al. MiR-122/cyclin G1 interaction modulates p53 activity and affects doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res 2009; 69 (14): 5761-7.
175. Fornari F, Milazzo M, Chieco P, et al. MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res 2010; 70 (12): 5184-93.
176. Ma K, He Y, Zhang H, et al. DNA methylation-regulated miR-193a-3p dictates resistance of hepatocellular carcinoma to 5-fluorouracil via repression of SRSF2 expression. J Biol Chem 2012; 287 (8): 5639-49.
177. Tomimaru Y, Eguchi H, Nagano H, et al. MicroRNA-21 induces resistance to the anti-tumour effect of interferon-alpha/5-fluorouracil in hepatocellular carcinoma cells. Br J Cancer 2010; 103 (10): 1617-26.
178. Tomokuni A, Eguchi H, Tomimaru Y, et al. miR-146a suppresses the sensitivity to interferon-alpha in hepatocellular carcinoma cells. Biochem Biophys Res Commun 2011; 414 (4): 675-80.